뇌척수액과 말초혈액 내 알츠하이머병의 생화학적 생체표지자

• 영문명: Biochemical Biomarkers for Alzheimer’s Disease in Cerebrospinal Fluid and Peripheral Blood
• 발행기관: 대한노인정신의학회
• 저자명: 이영민(Young Min Lee) 최원정(Won-Jung Choi) 박민선(Minsun Park) 김어수(Eosu Kim)
• 간행물 정보: 『노인정신의학』노인정신의학 제16권 제1호, 17~23쪽, 전체 7쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 2012.06.30

영문 초록

The diagnosis of Alzheimer’s disease (AD) is still obscure even to specialists. To improve the diagnostic accuracy, to find at-risk people as early as possible, to predict the efficacy or adverse reactions of pharmacotherapy on an individual basis, to attain more reliable results of clinical trials by recruiting better defined participants, to prove the disease-modifying ability of new candidate drugs, to establish prognosis-based therapeutic plans, and to do more, is now increasing the need for biomarkers for AD. Among AD-related biochemical markers, cerebrospinal beta-amyloid and tau have been paid the most attention since they are materials directly interfacing the brain interstitium and can be obtained through the lumbar puncture. Level of beta-amyloid is reduced whereas tau is increased in cerebrospinal fluid of AD patients relative to cognitively normal elderly people. Remarkably, such information has been found to help predict AD conversion of mild cognitive impairment. Despite inconsistent findings from previous studies, plasma beta-amyloid is thought to be increased before the disease onset, but show decreasing change as the disease progress. Regarding other peripheral biochemical markers, omics tools are being widely used not only to find useful biomarkers but also to generate novel hypotheses for AD pathogenesis and to lead new personalized future medicine.

목차

서론

뇌척수액 지표

혈액지표

결론

REFERENCES

키워드

알츠하이머병 생체표지자 베타 아밀로이드 타우 오믹스 혈장 Alzheimer’s disease Biomarker Beta-amyloid Tau Omics Plasma